Celldex Therapeutics (CLDX) FCF Margin Growth (3y) (2013 - 2026)
Powered by 
Analysis
Celldex Therapeutics (CLDX) FCF Margin Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | -1,272.00 |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | -2,228.00 |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -5,426.00 |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 9,545.00 |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 4,612.00 |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | -3,088.00 |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 14,060.00 |
| 10 | Celldex Therapeutics | 3.08 Bn | 3.08 Bn | -2.57 Mn | -26.51 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -26.51 Mn |
| Mar 31, 2026 | -44.52 Mn |
| Dec 31, 2025 | -5.25 Mn |
| Jun 30, 2025 | 793,170.00 |
| Mar 31, 2025 | 656,902.00 |
| Dec 31, 2024 | 162,594.00 |
| Sep 30, 2024 | 907,033.00 |
| Jun 30, 2024 | -83,806.00 |
| Mar 31, 2024 | -2.35 Mn |
| Dec 31, 2023 | -65,949.00 |
| Sep 30, 2023 | 53,719.00 |
| Jun 30, 2023 | -516,007.00 |
| Mar 31, 2023 | -256,236.00 |
| Dec 31, 2022 | -11,176.00 |
| Sep 30, 2022 | -666,515.00 |
| Jun 30, 2022 | -1.25 Mn |
| Mar 31, 2022 | -1.35 Mn |
| Dec 31, 2021 | -357,029.00 |
| Sep 30, 2021 | -928,618.00 |
| Jun 30, 2021 | 29,466.00 |